#395 - Brain lipidology: understanding APOE, cholesterol homeostasis, Alzheimer's disease risk, and the effects of lipid-lowering therapies on brain health | Tom Dayspring, M.D.

Episode Summary

Executive Summary: Peter Attia and Dr. Tom Dayspring explain how cholesterol is transported differently in the body versus the brain, emphasizing that brain lipid homeostasis is largely separate from the periphery. They connect APOE genotype to Alzheimer’s risk, discuss how cholesterol balance influences amyloid and tau biology, and review what is known about statins, ezetimibe, omega-3s, and CETP inhibitors for brain health.

Main Topics: Peripheral cholesterol transport and ApoB/ApoA biology (Priority: 5/5): Dayspring reviews how cholesterol circulates in lipoproteins: ApoA1-based HDL for cholesterol efflux and ApoB-containing particles (chylomicrons, VLDL, LDL) for return to the liver. He stresses that ApoB particle number, not just cholesterol content, drives atherosclerosis. Brain cholesterol is largely independent from plasma cholesterol (Priority: 5/5): The brain synthesizes and manages its own cholesterol because ApoB lipoproteins cannot cross the blood-brain barrier. Astrocytes, oligodendrocytes, and neurons participate in local production and transport using ApoE-containing HDL-like particles. APOE genotype, brain lipoproteins, and Alzheimer’s risk (Priority: 5/5): The discussion explains APOE isoforms (2, 3, 4), how they alter ApoE protein function, and why APOE4 is associated with impaired lipid transport, dysfunctional brain HDL particles, and higher Alzheimer’s disease risk. Cholesterol homeostasis, amyloid, and tau pathology (Priority: 5/5): They link cholesterol in neuronal membranes to APP processing. Excess membrane cholesterol favors beta-/gamma-secretase cleavage and more toxic amyloid-beta 42, while disturbed brain cholesterol balance may also contribute to tau-related pathology. Biomarkers of brain cholesterol metabolism (Priority: 4/5): The conversation highlights desmosterol as a plasma marker reflecting brain cholesterol synthesis and 24S-hydroxycholesterol as a marker of neuronal cholesterol efflux and brain stress, although the latter is mostly research-based. Effects of lipid-lowering therapies on the brain (Priority: 5/5): They review statins, ezetimibe, omega-3s, and CETP inhibitors. Statins enter the brain and may be neutral or beneficial overall but could theoretically over-suppress cholesterol synthesis in some people. Ezetimibe may have indirect brain effects via a metabolite. Omega-3s are plausibly beneficial. CETP inhibition may improve Alzheimer’s biomarkers. Translational implications for prevention and research (Priority: 4/5): The episode argues for earlier, risk-stratified intervention, especially in APOE4 carriers, and for more biomarker-driven trials that examine cognition and Alzheimer’s markers alongside cardiovascular endpoints.

Key Arguments: Atherosclerosis is fundamentally driven by ApoB-containing particles entering the artery wall; lowering ApoB reduces events because fewer particles can diffuse into plaques. HDL cholesterol levels alone are a poor proxy for HDL function; HDL particles have multiple non-cholesterol roles, including immune and anti-inflammatory functions. The brain does not depend on peripheral LDL/HDL cholesterol supply for normal function; it produces and recycles its own cholesterol locally. APOE4 likely increases Alzheimer’s risk partly by creating less functional brain HDL-like particles, impairing neuronal cholesterol delivery and altering membrane composition. Neuronal membrane cholesterol influences APP processing: high/abnormal cholesterol favors more pathogenic amyloid-beta production. The brain has an export mechanism for excess cholesterol via 24S-hydroxycholesterol, which can be measured in plasma as a research biomarker of brain cholesterol handling. Statins can enter the brain and likely do not generally harm cognition; some data suggest neutrality or benefit, though over-suppression may theoretically cause transient brain fog in susceptible people. Ezetimibe may have brain-relevant effects despite acting in the gut, possibly through its glucuronide metabolite and downstream effects on brain protein glycosylation/inflammation. Omega-3 status likely supports brain membrane health, but evidence is mostly observational rather than definitive randomized evidence. CETP inhibitors are interesting because they may improve ApoB lowering and also shift HDL/ApoA1 biology in ways that could favor brain biomarker profiles, especially in APOE4 carriers.

Data Points: Population genotype frequency: ~55% E3/E3 - Peter Attia estimates E3/E3 as the most common APOE genotype in the general population. Population genotype frequency: ~20–25% E3/E4 - Estimated prevalence of APOE4 heterozygosity. Population genotype frequency: ~1–2% E4/E4 - Estimated prevalence of APOE4 homozygosity. Alzheimer’s risk increase: ~2x to 3x - Peter describes APOE3/E4 risk versus APOE3/E3 as about two- to three-fold higher. Alzheimer’s risk increase: ~8x to 12x - Peter describes APOE4/E4 risk versus APOE3/E3 as roughly an order of magnitude higher in modern series. ApoB particle residence time: 3–5 days - Dayspring notes LDL particles can persist in plasma for several days. HDL proportion of lipoproteins: ~90% - Dayspring states HDLs make up most lipoprotein particles by number, though not by cholesterol mass. Total body cholesterol: ~140 g - Discussion of approximate whole-body cholesterol mass. Brain cholesterol content: ~20–25 g - Estimated cholesterol content of the brain. Liver cholesterol content: ~3–5 g - Estimated cholesterol content of the liver. Brain-to-liver cholesterol ratio: ~20x higher in brain - Dayspring emphasizes the brain stores far more cholesterol than the liver. Cholesterol synthesis cost: >30 ATP per molecule - Dayspring explains neuronal cholesterol synthesis is energetically expensive. Brain cholesterol half-life: ~5 years - Brain cholesterol turnover is far slower than in the periphery. Age of major brain growth: Birth to ~10 years - The brain is said to reach adult size around age 10, after which neurons largely stop making cholesterol. ApoB on particles: 1 ApoB per particle - Basis for using ApoB as a particle-number surrogate. Brain cholesterol efflux marker: 24S-hydroxycholesterol - Neuronal cholesterol disposal product used as a biomarker in research. Brain synthesis marker: Desmosterol - Plasma desmosterol correlates with CNS cholesterol synthesis and CSF desmosterol. Omega-3 target index: 8–9% - Bill Harris is cited as suggesting this omega-3 index range reflects adequate tissue status.

Pivotal Quotes: "The brain lipid and lipoprotein system that we're going to talk about has almost nothing to do with the plasma transportation of lipids and lipoproteins." — Tom Dayspring: Core framing statement distinguishing brain from peripheral cholesterol biology. "If cholesterol gets in your artery wall, you have the disease, and it's the ApoB particles bringing them in." — Tom Dayspring: Atherosclerosis mechanism and why ApoB lowering matters. "The neuron says, I've got to get rid of cholesterol... it will make cholesterol change into 24S hydroxycholesterol, which is water-soluble." — Tom Dayspring: Explains neuronal cholesterol export and the biomarker rationale.

Implications: Listeners should separate cardiovascular lipid management from brain cholesterol biology: ApoB lowering remains crucial for heart and vascular protection, while brain health may depend on APOE function, local cholesterol balance, and biomarkers such as desmosterol/24S-hydroxycholesterol. Future trials may identify which lipid-lowering therapies help cognition, especially in APOE4 carriers.